BriaCell Therapeutics Corp. (BCTX) stock
BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
$3.51−0.08 (-2.23%)
Close on Nov 12, 2026Market cap $30.65MP/E –Yield –
BriaCell Therapeutics total assets
Total assets on the balance sheet at the end of each period.
BriaCell Therapeutics's total assets was $23.58M at Jul 31, 2026. For fiscal 2026 it was $23.58M, up 8.9% from the year before. The highest annual figure on record is $58.04M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | $23.58M | +8.9% |
| FY2025 | Jul 31, 2025 | $21.65M | +268.7% |
| FY2024 | Jul 31, 2024 | $5.87M | -78.4% |
| FY2023 | Jul 31, 2023 | $27.16M | -36.2% |
| FY2022 | Jul 31, 2022 | $42.58M | -26.6% |
| FY2021 | Jul 31, 2021 | $58.04M | +11012.4% |
| FY2020 | Jul 31, 2020 | $522.33K | +17.5% |
| FY2019 | Aug 1, 2019 | $444.66K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | $23.58M | +8.9% |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | $27.07M | +59.2% |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | $33.59M | +258.8% |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | $13.08M | +25.5% |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | $21.65M | +268.7% |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | $17.00M | +174.1% |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | $9.36M | -23.4% |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | $10.41M | -44.1% |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | $5.87M | -78.4% |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | $6.20M | -79.1% |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | $12.23M | -64.2% |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | $18.62M | -51.6% |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | $27.16M | -36.2% |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | $29.72M | -36.0% |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | $34.16M | -29.6% |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | $38.45M | -33.8% |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | $42.58M | +8051.4% |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | $46.46M | +10348.7% |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | $48.55M | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | $58.04M | – |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | $522.33K | – |
| Q4 FY2019CQ2 2019 | Aug 1, 2019 | $444.66K | – |
See a number that looks wrong?